Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 1243.3% from a year ago
Other current liabilities stood at $45.44M at the end of Q1 FY2026, up 1243.3% from a year earlier and up 10.2% from the prior quarter. Over 3 fiscal years it compounded at +111.9% a year.
Context
- Other current liabilities amounted to 6.1% of total assets at the end of Q1 FY2026, up 5.1 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +1243.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 41.23M USD
- Year-over-year change
- +396.2%
- 3-year CAGR
- +111.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.23M | +396.2% |
| FY2024 | 2024-12-31 | 8.31M | +62.2% |
| FY2023 | 2023-12-31 | 5.12M | +18.3% |
| FY2022 | 2022-12-31 | 4.33M | — |
Other Current Liabilities vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 other current liabilities of $45.44M is the 2nd highest of the 8 companies compared; the peer median is $4.86M.
- Its year-over-year change of +1243.3% is the highest of 7, against a peer median of +9.3%.
- Other current liabilities amounts to 6.1% of total assets for ZBIO, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $104.02M | +892.5% | +263.2% | 13.7% | |
| Mar 2026 | $45.44M | +1243.3% | +111.9% | 6.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $11.24M | +1184.0% | +123.8% | 3.5% |
| Mar 2026 | $6.06M | -39.9% | -8.8% | 3.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $4.86M | — | — | 1.7% |
| Mar 2026 | $3.78M | +4.6% | +8.2% | 5.9% | |
| Mar 2026 | $2.71M | +14.1% | +254.6% | 1.0% | |
| Dec 2025 | -$3K | -125.0% | — | 0.0% | |
| Peer median (excluding ZBIO) | $4.86M | +9.3% | +123.8% | 3.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.